Osteoclasts and tumor cells contribute to bone destruction, and neurotrophins, cytokines (IL-1β and TNFα), and other factors (ATP, TGFβ1, IGF-1, and sclerostin) play roles, suggesting potential intervention targets for improved pain management and enhanced patient quality of life [150]. The gene discussed is IGF1; the disease is neoplasm.